Trial Profile
A clinical study for the efficacy and safety of apatinib mesylate in treament of gastric cancer in the real world
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 29 Oct 2018 New trial record